Related Experiment Video

Updated: Apr 27, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K

A single nucleotide polymorphism in the stromal cell-derived factor 1 gene is associated with coronary heart disease

Lei Feng1, Shi-Yan Nian2, Ying-Lu Hao3

  • 1Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. fengleii@kmmu.edu.cn.

International Journal of Molecular Sciences
|June 21, 2014
PubMed

Insights

Genetic variations in the stromal cell-derived factor 1 (SDF-1) gene are linked to coronary heart disease (CHD). The GG genotype of rs1801157 is an independent risk factor for CHD in the Chinese population.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Molecular Biology

Background:

  • Coronary heart disease (CHD) is a leading global cause of mortality.
  • Genetic predisposition is a significant non-modifiable risk factor for CHD.
  • The stromal cell-derived factor 1 (SDF-1) gene plays a role in cardiovascular health.

Purpose of the Study:

  • To investigate the association between a specific single nucleotide polymorphism (SNP) in the SDF-1 gene (rs1801157) and the risk of CHD.
  • To identify genetic and clinical risk factors for CHD in a Chinese population.

Main Methods:

  • Recruited 84 Chinese patients with CHD and 253 healthy controls.
  • Genotyped the SDF-1 rs1801157 polymorphism.
  • Utilized multivariate logistic regression analysis to evaluate associations with CHD.

Main Results:

  • The GG genotype of SDF-1 rs1801157 was significantly more frequent in the CHD group (59.5%) compared to controls (49.8%) (p=0.036).
  • The GG genotype was identified as an independent risk factor for CHD (OR=2.31, 95% CI=1.21-5.23).
  • Male sex, advanced age, hypertension, and elevated LDL-C, low HDL-C, and high TG levels were also independent risk factors.

Conclusions:

  • The GG genotype of the SDF-1 rs1801157 polymorphism is associated with an increased risk of coronary heart disease in the studied Chinese population.
  • This genetic variant, along with established clinical factors, contributes to CHD development.
  • Further research may elucidate the functional mechanisms linking SDF-1 variants to CHD pathogenesis.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189